Prestige Consumer Healthcare (FRA:PBV) Risk Assessment

View and export this data going back to 2005. Start your Free Trial

What is Prestige Consumer Healthcare Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Prestige Consumer Healthcare is: No Data: Cannot be evaluated.

Competitive Comparison of Prestige Consumer Healthcare's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prestige Consumer Healthcare's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Prestige Consumer Healthcare's Risk Assessment falls into.

Prestige Consumer Healthcare (FRA:PBV) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Prestige Consumer Healthcare Risk Assessment Related Terms

Thank you for viewing the detailed overview of Prestige Consumer Healthcare's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Prestige Consumer Healthcare (FRA:PBV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Prestige Consumer Healthcare Inc (FRA:PBV) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

PBH:USA

Address

660 White Plains Road, Tarrytown, NY, USA, 10591

Website

https://www.prestigebrands.com

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Prestige Consumer Healthcare (FRA:PBV) Headlines

No Headlines